Compound 15c, a Novel Dual Inhibitor of EGFR<sup>L858R/T790M</sup> and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers.

导出 LinkOut

翻译打印收藏纠错

作者： Gaozhi,Chen ^[1] ; Yuyan,Bao ^[2] ; Qiaoyou,Weng ^[3] ; Yingxin,Zhao ^[4] ; Xiaoyao,Lu ^[1] ; Lili,Fu ^[1] ; Lingfeng,Chen ^[1] ; Zhiguo,Liu ^[1] ; Xiaomin,Zhang ^[1] ; Guang,Liang ^[3]

作者单位： Chemical Biology Research Center, School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China. ^[1] Engineering Laboratory of Zhejiang Province for Pharmaceutical Development of Growth Factors, Biomedical Collaborative Innovation Center of Wenzhou, Wenzhou, China. ^[2] Department of Pharmacy, Sanmen People's Hospital of Zhejiang, Sanmen, China. ^[3] Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China. ^[4]

关键词 EGFR FGFR1 NSCLC drug resistance kinase inhibitor

DOI 10.3389/fphar.2019.01533

PMID 31998131

发布时间 2020-09-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in pharmacology

2019年10卷

1533页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Compound 15c, a Novel Dual Inhibitor of EGFR<sup>L858R/T790M</sup> and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Compound 15c, a Novel Dual Inhibitor of EGFR<sup>L858R/T790M</sup> and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除